Clindamycin

Pharmacologic Category

Antibiotic, Lincosamide

Dosing: Adult

Usual dose:

Oral: 600 to 1,800 mg/day in 2 to 4 divided doses; up to 2,400 mg/day in 4 divided doses may be given for severe infections.

IM, IV: 600 to 2,700 mg/day in 2 to 4 divided doses; according to the manufacturer, up to 4,800 mg/day IV (in divided doses) has been used in life-threatening infections; however, data supporting this dose are lacking; maximum: 600 mg/dose IM.

Anthrax (off-label use): Note: Consult public health officials for event-specific recommendations.

Inhalational exposure postexposure prophylaxis (alternative agent): Oral: 600 mg every 8 hours for 60 days. Note: Anthrax vaccine should also be administered to exposed individuals (CDC [Hendricks 2014]).

Cutaneous, without systemic involvement, empiric therapy (alternative agent): Oral: 600 mg every 8 hours for 60 days following biological weapon-related event; duration is 7 to 10 days after naturally acquired infection. Note: Patients with cutaneous lesions of the head or neck or extensive edema should be treated for systemic involvement (CDC [Hendricks 2014]).

Systemic, meningitis excluded: IV: 900 mg every 8 hours in combination with other appropriate agents for at least 2 weeks or until clinically stable, whichever is longer (CDC [Hendricks 2014]).

Meningitis (alternative agent): IV: 900 mg every 8 hours in combination with other appropriate agents for at least 2 to 3 weeks or until clinically stable, whichever is longer (CDC [Hendricks 2014]).

Note: Antitoxin should also be administered for systemic anthrax. Following the course of IV combination therapy for systemic anthrax infection (including meningitis), patients exposed to aerosolized spores require oral monotherapy to complete a total antimicrobial course of 60 days (CDC [Hendricks 2014]).

Babesiosis (off-label use):

Mild to moderate disease: Oral: 600 mg every 8 hours in combination with quinine for 7 to 10 days (IDSA [Wormser 2006]).

Severe disease: IV: 600 mg every 6 hours for 7 to 10 days in combination with quinine (IDSA [Wormser 2006]; Krause 2019); a longer duration is needed for those at high risk for relapse (Krause 2008; Sanchez 2016; Vannier 2012). Clindamycin can be given orally once symptoms have abated and parasitemia is reduced (Krause 2019; Sanchez 2016).

Bacterial vaginosis (alternative agent) (off-label use): Oral: 300 mg twice daily for 7 days (CDC [Workowski 2015]).

Bite wound, prophylaxis or treatment, animal or human bite (alternative agent) (off-label use): Note: For animal bite, use in combination with an appropriate agent for Pasteurella multocida. For human bite, use in combination with an appropriate agent for Eikenella corrodens (IDSA [Stevens 2014]).

Oral: 300 to 450 mg 3 times daily (Baddour 2019a; Baddour 2019b; IDSA [Stevens 2014]).

IV: 600 mg every 6 to 8 hours (IDSA [Stevens 2014]). Note: In selected patients with high-risk wounds, some experts recommend parenteral therapy be given initially until infection is resolving, followed by oral therapy (Baddour 2019a; Baddour 2019b).

Note: For prophylaxis, duration is 3 to 5 days (IDSA [Stevens 2014]); for treatment of established infection, duration is typically 5 to 14 days and varies based on patient-specific factors, including clinical response (Baddour 2019a; Baddour 2019b).

Diabetic foot infection, mild to moderate (alternative agent) (off-label use): Oral: 300 to 450 mg every 6 to 8 hours (Bader 2008; IDSA [Lipsky 2012]; Lipsky 1990; Weintrob 2018). Note: May be used alone for empiric therapy of mild infections; if there are risk factors for gram-negative bacilli, must be used in combination with other appropriate agents. Duration of therapy should be tailored to individual clinical circumstances; most patients respond to 1 to 2 weeks of therapy (IDSA [Lipsky 2012]; Weintrob 2018).

Endocarditis, prophylaxis (dental or invasive respiratory tract procedures) (alternative agent for penicillin-allergic patients) (off-label use):

Oral: 600 mg as a single dose 30 to 60 minutes prior to procedure (AHA [Wilson 2007]).

IM, IV: 600 mg as a single dose 30 to 60 minutes before procedure (only if unable to tolerate or absorb oral therapy) (AHA [Wilson 2007]).

Note: Only recommended for patients with cardiac conditions associated with the highest risk of an adverse outcome from endocarditis and who are undergoing a procedure likely to result in bacteremia with an organism that has the potential ability to cause endocarditis (AHA [Wilson 2007]).

Hidradenitis suppurativa (off-label use): Oral: 300 mg twice daily in combination with rifampin for 10 to 12 weeks (Dessinioti 2016; Gener 2009; Gulliver 2016; Zouboulis 2015).

Malaria (off-label use):

Uncomplicated malaria, treatment, chloroquine-resistant or unknown resistance (alternative agent): Oral: 20 mg/kg/day in divided doses every 8 hours for 7 days in combination with quinine sulfate. Note: Quinine sulfate duration is region specific (CDC 2013).

Severe malaria, treatment: IV: Loading dose: 10 mg/kg followed by 5 mg/kg every 8 hours in combination with IV quinidine gluconate; may switch to oral therapy (clindamycin plus quinine sulfate) when tolerated. Note: Duration of clindamycin is 7 days. Quinine sulfate duration is region specific (CDC 2013).

Neutropenic fever, empiric therapy for low-risk cancer patients (alternative agent for penicillin-allergic patients) (off-label use): Oral: 600 mg every 8 hours (Rubenstein 1993); some experts recommend 300 mg every 6 hours (Bow 2018) (data on appropriate dose are limited). Use in combination with oral ciprofloxacin; continue until afebrile and neutropenia has resolved. Note: Avoid in patients who have received fluoroquinolone prophylaxis. Administer first dose in the health care setting (after blood cultures are drawn); observe patient for ≥4 hours before discharge (ASCO/IDSA [Taplitz 2018]; IDSA [Freifeld 2011]).

Odontogenic infection (alternative agent for penicillin-allergic patients) (off-label use):

IV: 600 mg every 8 hours until improved, then transition to oral clindamycin (Bhagania 2018; Chow 2018).

Oral (initial therapy for mild infection or step-down after parenteral treatment): 450 mg every 8 hours to complete a 7- to 14-day course (Chow 2018); doses in the literature varied from 150 mg every 6 hours (Tancawan 2015) to 300 mg every 6 hours (Cachovan 2011) to 600 mg every 8 hours (Bhagania 2018).

Osteomyelitis:

Osteomyelitis due to methicillin-resistant Staphylococcus aureus (MRSA) (alternative agent): IV, Oral: 600 mg 3 times daily for a minimum of 8 weeks; some experts combine with rifampin (IDSA [Liu 2011]).

Osteomyelitis, native vertebral due to staphylococci, methicillin-susceptible (alternative agent):

IV: 600 to 900 mg every 8 hours for 6 weeks (IDSA [Berbari 2015]).

Oral: 300 to 450 mg 4 times daily (IDSA [Berbari 2015]) or 600 mg 3 times daily (IDSA [Liu 2011]) for 6 weeks (IDSA [Berbari 2015]). Note: Clindamycin may also be used as suppressive therapy in selected patients (Osmon 2019).

Osteomyelitis, native vertebral due to Cutibacterium acnes (alternative agent): IV: 600 to 900 mg every 8 hours for 6 weeks (IDSA [Berbari 2015]).

Pelvic inflammatory disease, severe: IV: 900 mg every 8 hours with gentamicin; after 24 to 48 hours of sustained clinical improvement, transition to clindamycin 450 mg orally 4 times daily (or oral doxycycline) to complete 14 days of therapy. Note: If tubo-ovarian abscess is present, oral clindamycin should be given in combination with doxycycline to complete at least 14 days of therapy rather than giving doxycycline alone (CDC [Workowski 2015]).

Pneumocystis jirovecii pneumonia (PCP), treatment (alternative agent) (off-label use):

Mild to moderate disease: Oral: 450 mg every 6 hours or 600 mg every 8 hours with primaquine for 21 days (HHS [OI adult 2017]).

Severe disease: IV: 600 mg every 6 hours or 900 mg every 8 hours with primaquine for 21 days; following clinical improvement, clindamycin can be given orally at 450 mg every 6 hours or 600 mg every 8 hours (HHS [OI adult 2017]; Thomas 2018).

Note: Patients with moderate or severe infection (PaO2 <70 mm Hg at room air or alveolar-arterial oxygen gradient ≥35 mm Hg) should receive adjunctive glucocorticoids (HHS [OI adult 2017]).

Pneumonia due to MRSA (alternative agent) (off-label use): Oral, IV: 600 mg 3 times daily; duration is for a minimum of 7 days and varies based on disease severity and response to therapy (IDSA [Liu 2011]).

Postpartum endometritis: IV: 900 mg every 8 hours plus gentamicin; treat until the patient is clinically improved (no fundal tenderness) and afebrile for 24 to 48 hours (Chen 2018; Gall 1996).

Prosthetic joint infection (off-label use):

Cutibacterium acnes, treatment (alternative agent for penicillin allergy):

IV: 600 to 900 mg every 8 hours for 4 to 6 weeks (IDSA [Osmon 2013]).

Oral: 300 to 450 mg every 6 hours (IDSA [Osmon 2013]), following at least 2 weeks of parenteral therapy (Kanafani 2018).

Methicillin-resistant staphylococci, treatment (chronic suppression): Oral: 600 mg every 8 hours (Berbari 2019).

Rhinosinusitis, acute bacterial (alternative agent for penicillin-allergic patients able to tolerate cephalosporins with concern for pneumococcal resistance) (off-label use): Oral: 300 mg every 6 to 8 hours in combination with a third-generation cephalosporin (eg, cefixime or cefpodoxime) for 5 to 7 days (IDSA [Chow 2012]; Patel 2018; Rosenfeld 2016). Note: In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients (AAO-HNS [Rosenfeld 2015]; Harris 2016).

Septic arthritis due to Staphylococcus aureus (including MRSA) (alternative agent): Oral, IV: 600 mg 3 times daily for 3 to 4 weeks (Goldenberg 2018; IDSA [Liu 2011]). Note: A longer course of parenteral therapy (4 weeks) may be required for patients with concomitant bacteremia (in the absence of endocarditis) (Goldenberg 2019).

Skin and soft tissue infection:

Impetigo or ecthyma if MRSA is suspected or confirmed (alternative agent): Oral: 300 mg 4 times daily or 450 mg 3 times daily for 7 days (Baddour 2020; IDSA [Stevens 2014]).

Nonpurulent cellulitis or erysipelas due to beta-hemolytic streptococci or Staphylococcus aureus (including MRSA), empiric or pathogen-directed therapy (alternative agent):

Oral: 300 mg 4 times daily or 450 mg 3 times daily.

IV: 600 mg to 900 mg every 8 hours.

Note: Transition to oral therapy once improving; treat for at least 5 days but may extend to 14 days depending on severity and clinical response (IDSA [Stevens 2014]; Spelman 2020).

Purulent cellulitis or abscess due to S. aureus (including MRSA) or beta-hemolytic streptococci (alternative agent):

Oral: 300 mg 4 times daily or 450 mg 3 times daily. Treat for 5 to 14 days depending on severity and clinical response.

Note: Systemic antibiotics only indicated for certain instances (eg, immunocompromised patients, signs of systemic infection, large or multiple abscess, indwelling device, high risk for adverse outcome with endocarditis). If at risk for gram-negative bacilli, use in combination with an appropriate agent (IDSA [Stevens 2014]; Spelman 2020).

Necrotizing soft tissue infection (alternative agent): IV: 600 to 900 mg every 8 hours as part of an appropriate combination regimen. Note: Antibiotic therapy must be used in conjunction with early and aggressive surgical exploration and debridement of necrotic tissue (IDSA [Stevens 2014]; Stevens 2018).

Streptococcus (group A):

Bloodstream infection: IV: 900 mg every 8 hours in combination with IV penicillin G; duration is individualized, but clindamycin may be discontinued within 48 hours for patients without septic shock, organ failure, or necrotizing infection. Continue penicillin G to complete ≥14 days of therapy (Stevens 2019).

Pharyngitis (alternative agent for penicillin-allergic patients) (off-label use): Oral: 300 mg 3 times daily for 10 days (IDSA [Shulman 2012]).

Chronic carriage (off-label use): Oral: 300 mg 3 times daily for 10 days. Note: Most individuals with chronic carriage do not require antimicrobial treatment (IDSA [Shulman 2012]).

Streptococcus (group B), maternal prophylaxis for prevention of neonatal disease (alternative agent) (off-label use):

Note: Prophylaxis is reserved for pregnant women with a positive group B streptococci (GBS) vaginal or rectal screening in late gestation or GBS bacteriuria during the current pregnancy, history of birth of an infant with early-onset GBS disease, and unknown GBS culture status with any of the following: birth <37 0/7 weeks gestation, intrapartum fever, prolonged rupture of membranes, known GBS positive in a previous pregnancy, or intrapartum nucleic acid amplification testing positive for GBS (ACOG 2019).

IV: 900 mg at onset of labor or prelabor rupture of membranes, then every 8 hours until delivery. Note: Clindamycin should be reserved for penicillin-allergic patients at high risk for anaphylaxis (ACOG 2019).

Surgical prophylaxis (in combination with other appropriate agents when coverage for MRSA is indicated or for gram-positive coverage in patients unable to tolerate cephalosporins) (off-label use): IV: 900 mg started within 60 minutes prior to initial surgical incision. Clindamycin doses may be repeated intraoperatively at 6-hour intervals if procedure is lengthy or if there is excessive blood loss (ASHP/IDSA/SIS/SHEA [Bratzler 2013]). In cases where an extension of prophylaxis is warranted postoperatively, total duration should be ≤24 hours (Anderson 2014; ASHP/IDSA/SIS/SHEA [Bratzler 2013]). For clean and clean-contaminated procedures, continued prophylactic antibiotics beyond surgical incision closure is not recommended, even in the presence of a drain (CDC [Berríos-Torres 2017]).

Toxic shock syndrome, toxin production suppression (empiric therapy): IV: 900 mg every 8 hours as part of an appropriate combination regimen (Lappin 2009; Wong 2013). Duration is until clinically and hemodynamically stable for at least 48 to 72 hours; then discontinue clindamycin and give monotherapy with an appropriate agent (Chu 2019; Stevens 2019).

Toxoplasma gondii encephalitis and pneumonitis (alternative agent) (off-label use):

Initial treatment: Oral, IV: 600 mg every 6 hours in combination with pyrimethamine and leucovorin. Continue therapy for at least 6 weeks; longer duration may be required if incomplete response or extensive disease; after completion of acute therapy, all patients should receive long-term maintenance therapy (HHS [OI adult 2017]; Schwartz 2013).

Long-term maintenance therapy: Oral: 600 mg every 8 hours in combination with pyrimethamine and leucovorin (HHS [OI adult 2017]; Schwartz 2013); in HIV-infected patients, may discontinue when asymptomatic with a CD4 count >200 cells/mm3 and an undetectable HIV viral load for >6 months in response to ART (HHS [OI adult 2017]).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP; Michael Heung, MD, MS.

IV, Oral:

Mild to severe impairment: No dosage adjustment necessary.

Hemodialysis, intermittent (thrice weekly): Poorly dialyzed; no supplemental dose or dosage adjustment necessary (Cimino 1969).

Peritoneal dialysis: Poorly dialyzed; no dosage adjustment necessary (Malacoff 1975).

CRRT: No dosage adjustment necessary (Heintz 2009).

PIRRT (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (expert opinion).

Dosing: Hepatic Impairment: Adult

Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling.

Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer's labeling. In studies of patients with moderate or severe liver disease, half-life is prolonged; however, when administered on an every-8-hour schedule, accumulation should rarely occur. In severe liver disease, use caution and monitor liver enzymes periodically during therapy.

Dosing: Pediatric

General dosing, susceptible infection:

IM, IV:

Manufacturer's labeling: Infants, Children, and Adolescents 1 month to 16 years:

Weight-directed dosing: 20 to 40 mg/kg/day divided every 6 to 8 hours.

BSA-directed dosing: 350 to 450 mg/m2/day divided every 6 to 8 hours.

Alternate dosing (Red Book [AAP] 2012): Infants, Children, and Adolescents:

Mild to moderate infections: 20 mg/kg/day divided every 8 hours; maximum daily dose: 1,800 mg/day.

Severe infections: 40 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 2,700 mg/day.

Oral:

Manufacturer's labeling: Infants, Children, and Adolescents:

Hydrochloride salt (capsule): 8 to 20 mg/kg/day divided every 6 to 8 hours.

Palmitate salt (solution): 8 to 25 mg/kg/day divided every 6 to 8 hours; minimum dose: 37.5 mg 3 times daily.

Alternate dosing (Red Book [AAP]; 2012): Infants, Children, and Adolescents:

Mild to moderate infections: 10 to 25 mg/kg/day divided every 8 hours; maximum daily dose: 1,800 mg/day.

Severe infections: 30 to 40 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 1,800 mg/day.

Babesiosis: Infants, Children, and Adolescents: Oral: 20 to 40 mg/kg/day divided every 8 hours for 7 to 10 days plus quinine; maximum single dose: 600 mg (Red Book [AAP] 2012).

Bacterial endocarditis prophylaxis for dental and upper respiratory procedures in penicillin-allergic patients (Red Book [AAP] 2012; Wilson 2007): Infants, Children, and Adolescents:

IM, IV: 20 mg/kg 30 minutes before procedure; maximum single dose: 600 mg.

Oral: 20 mg/kg 1 hour before procedure; maximum single dose: 600 mg.

Note: American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.

Catheter (peritoneal dialysis); exit-site or tunnel infection: Infant, Children, and Adolescents: Oral: 10 mg/kg/dose 3 times daily; maximum dose: 600 mg/dose (Warady [ISPD 2012]).

Intra-abdominal infection, complicated: Infants, Children, and Adolescents: IV: Note: Not recommended for community-acquired infections due to increasing Bacteroides fragilis resistance: 20 to 40 mg/kg/day divided every 6 to 8 hours in combination with gentamicin or tobramycin (Solomkin 2010).

Malaria, treatment: Infants, Children, and Adolescents:

Uncomplicated: Oral: 20 mg/kg/day divided every 8 hours for 7 days plus quinine (CDC 2011; Red Book [AAP] 2012).

Severe: IV: Loading dose: 10 mg/kg once followed by 15 mg/kg/day divided every 8 hours plus IV quinidine gluconate; switch to oral therapy (clindamycin and quinine, see above) when able for total treatment duration of 7 days. Note: Quinine duration is region specific; consult CDC for current recommendations (CDC 2011).

Osteomyelitis, septic arthritis, due to MRSA: Infants, Children, and Adolescents: IV, Oral: 40 mg/kg/day divided every 6 to 8 hours for at least 4 to 6 weeks (osteomyelitis) or 3 to 4 weeks (septic arthritis) (IDSA [Liu 2011]).

Otitis media, acute: Infants ≥6 months, Children, and Adolescents: Oral: 30 to 40 mg/kg/day divided every 8 hours; administer with or without a third generation cephalosporin (AAP [Lieberthal 2013]).

Peritonitis (peritoneal dialysis):

Prophylaxis (Warady [ISPD 2012]):

Invasive dental procedures: Oral: 20 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 600 mg.

Gastrointestinal or genitourinary procedures: IV: 10 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 600 mg.

Treatment: Intraperitoneal, continuous: Loading dose: 300 mg per liter of dialysate; maintenance dose: 150 mg per liter; Note: 125 mg/liter has also been recommended as a maintenance dose (Aronoff 2007; Warady [ISPD 2012]).

Pharyngitis:

AHA guidelines (Gerber 2009): Children and Adolescents: Oral: 20 mg/kg/day in divided doses 3 times daily for 10 days; maximum single dose: 600 mg.

IDSA guidelines (Shulman, 2012): Children and Adolescents: Oral:

Treatment and primary prevention of rheumatic fever: 21 mg/kg/day in divided doses 3 times daily for 10 days; maximum single dose: 300 mg.

Treatment of chronic carriers: 20 to 30 mg/kg/day in divided doses 3 times daily for 10 days; maximum single dose: 300 mg.

Pneumococcal disease, invasive: Infants, Children, and Adolescents: IV: 25 to 40 mg/kg/day divided every 6 to 8 hours (Red Book [AAP] 2012).

Pneumocystis jirovecii (formerly carnii) pneumonia (PCP):

Non HIV-exposed/-positive (Red Book [AAP] 2012): Infants, Children, and Adolescents:

Mild to moderate disease: Oral: 10 mg/kg 3 to 4 times daily for 21 days; in combination with other agents; maximum single dose: 450 mg.

Moderate to severe disease: IV: 15 to 25 mg/kg 3 to 4 times daily for 21 days; give with pentamidine or primaquine; maximum single dose: 600 mg. May switch to oral dose after clinical improvement.

HIV-exposed/-positive: Adolescents (DHHS [adult] 2013):

Mild to moderate disease: Oral: 300 mg every 6 hours or 450 mg every 8 hours with primaquine for 21 days.

Moderate to severe disease:

Oral: 300 mg every 6 hours or 450 mg every 8 hours with primaquine for 21 days.

IV: 600 mg every 6 hours or 900 mg every 8 hours with primaquine for 21 days.

Pneumonia:

Community-acquired pneumonia (CAP) (IDSA/PIDS [Bradley 2011]): Infants ≥3 months, Children, and Adolescents: Note: In children ≥5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.

Moderate to severe infection: IV: 40 mg/kg/day divided every 6 to 8 hours.

Mild infection, step-down therapy: Oral: 30 to 40 mg/kg/day divided every 6 to 8 hours.

MRSA pneumonia: IV: 40 mg/kg/day divided every 6 to 8 hours for 7 to 21 days (IDSA [Liu 2011]).

Rhinosinusitis, acute bacterial: Children and Adolescents: Oral: 30 to 40 mg/kg/day divided every 8 hours with concomitant cefixime or cefpodoxime for 10 to 14 days. Note: Recommended in patients with nontype I penicillin allergy, after failure to initial therapy, or in patients at risk for antibiotic resistance (eg, daycare attendance, age <2 years, recent hospitalization, antibiotic use within the past month) (Chow 2012).

Skin and soft tissue infection: Infants, Children, and Adolescents:

Impetigo: Oral: 20 mg/kg/day in divided doses 3 times daily for 7 days; maximum dose: 400 mg/dose (IDSA [Stevens 2014]).

MRSA infection: Note: Treatment duration based on clinical response, usually 7 to 14 days for complicated skin and soft tissue infection and 5 to 10 days for outpatient cellulitis (nonpurulent or purulent) (IDSA [Liu 2011]).

IV: 25 to 40 mg/kg/day in divided doses 3 times daily (IDSA [Stevens 2014]) or 40 mg/kg/day in divided doses every 6 to 8 hours (IDSA [Liu 2011]); maximum dose: 600 mg/dose.

Oral: 30 to 40 mg/kg/day in divided doses 3 times daily (IDSA [Stevens 2014]) or 30 to 40 mg/kg/day in divided doses every 6 to 8 hours (IDSA [Liu 2011]); maximum dose: 450 mg/dose.

MSSA infection (IDSA [Stevens 2014]): Duration of treatment dependent upon site and severity of infection; cellulitis and abscesses that have been drained typically require 5 to 10 days of therapy.

IV: 25 to 40 mg/kg/day in divided doses 3 times daily; maximum dose: 600 mg/dose.

Oral: 25 to 30 mg/kg/day in divided doses 3 times daily; maximum dose: 450 mg/dose.

Necrotizing infections: IV: 10 to 13 mg/kg/dose every 8 hours; maximum dose: 900 mg/dose; may use in combination with other antibiotics based on organism. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).

Surgical prophylaxis: Children and Adolescents: IV: 10 mg/kg 30 to 60 minutes prior to the procedure; may repeat in 6 hours; maximum single dose: 900 mg (Bratzler 2013).

Toxoplasmosis (HIV-exposed/positive or hematopoietic cell transplantation recipients):

Infants and Children (CDC 2009; Red Book [AAP] 2012; Tomblyn 2009):

Treatment, HIV-exposed/-positive: IV, Oral: 5 to 7.5 mg/kg/dose 4 times daily with pyrimethamine and leucovorin; maximum single dose: 600 mg.

Secondary prevention:

HIV-exposed/-positive: Oral: 7 to 10 mg/kg/dose every 8 hours and pyrimethamine plus leucovorin; maximum single dose: 600 mg (DHHS [pediatric] 2013).

Hematopoietic cell transplantation recipients: Oral: 5 to 7.5 mg/kg/dose every 6 hours and pyrimethamine plus leucovorin; maximum single dose: 450 mg.

Adolescents (DHHS [adult] 2013; Red Book [AAP] 2012; Tomblyn 2009):

Treatment: Oral, IV: 600 mg every 6 hours with pyrimethamine and leucovorin for at least 6 weeks; longer if clinical or radiologic disease is extensive or response is incomplete.

Secondary prevention:

HIV-exposed/-positive: Oral: 600 mg every 8 hours with pyrimethamine and leucovorin.

Hematopoietic cell transplantation recipients: Oral: 300 to 450 mg every 6 to 8 hours with pyrimethamine and leucovorin.

Dosing: Renal Impairment: Pediatric

No adjustment required. Not dialyzable (0% to 5%).

Dosing: Hepatic Impairment: Pediatric

No adjustment required. Use caution with severe hepatic impairment.

Calculations

• Clindamycin: Dental

Use: Labeled Indications

Bone and joint infections: Treatment of bone and joint infections, including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections caused by susceptible organisms.

Gynecological infections: Treatment of gynecologic infections, including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Intraabdominal infections: Treatment of intraabdominal infections, including peritonitis and intraabdominal abscess caused by susceptible anaerobic organisms.

Lower respiratory tract infections: Treatment of lower respiratory tract infections, including pneumonia, empyema, and lung abscess caused by susceptible anaerobes, Streptococcus pneumoniae, other streptococci (except Enterococcus faecalis), and S. aureus.

Septicemia: Treatment of septicemia caused by S. aureus, streptococci (except E. faecalis), and susceptible anaerobes.

Skin and soft tissue infection: Treatment of skin and soft tissue infection caused by Streptococcus pyogenes, S. aureus, and susceptible anaerobes.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

AnthraxLevel of Evidence [G]

Based on the Centers for Disease Control and Prevention (CDC) expert panel meetings on prevention and treatment of anthrax in adults, clindamycin is an effective and acceptable alternative for postexposure prophylaxis or treatment of cutaneous anthrax; it is also a first-line option, in combination with other antimicrobials, for the treatment of systemic anthrax. Alternative regimens have also been suggested for other patient populations with anthrax, including injectable drug users who develop injectional anthrax Ref.

BabesiosisLevel of Evidence [G]

Based on the Infectious Diseases Society of America (IDSA) guidelines for the clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis, clindamycin (in combination with quinine) is an effective and recommended option for the treatment of babesiosis.

Bacterial vaginosisLevel of Evidence [G]

Based on the CDC sexually transmitted diseases treatment guidelines, oral clindamycin is an effective and recommended alternative agent for patients with bacterial vaginosis.

Bite wound, prophylaxis or treatment, animal or human biteLevel of Evidence [G]

Based on the IDSA guidelines for the diagnosis and management of skin and soft tissue infections, clindamycin, in combination with a second- or third-generation cephalosporin, levofloxacin, or sulfamethoxazole and trimethoprim, is an effective and recommended alternative for treatment of animal or human bite wounds.

Diabetic foot infection, mild to moderateLevel of Evidence [G]

Based on the IDSA guidelines for the diagnosis and treatment of diabetic foot infections, clindamycin is an effective and recommended alternative treatment option for mild diabetic foot infection due to S. aureus or Streptococcus spp and, in combination with ciprofloxacin or levofloxacin, for moderate diabetic foot infection

Endocarditis, prophylaxis (dental or invasive respiratory tract procedures) (alternative agent for penicillin-allergic patients)Level of Evidence [G]

Based on the American Heart Association (AHA) guidelines for the prevention of infective endocarditis, clindamycin is an effective and recommended alternative agent for the prevention of infective endocarditis associated with dental or respiratory tract procedures in patients with certain cardiac conditions who are allergic to penicillins or ampicillin.

Group B streptococci, maternal prophylaxis for prevention of neonatal diseaseLevel of Evidence [G]

Based on the American College of Obstetricians and Gynecologists (ACOG) Prevention of Group B Streptococcal Early-Onset Disease in Newborns guideline, the use of intravenous clindamycin is effective and recommended in patients at high risk for anaphylaxis due to penicillin allergy if the GBS isolate is sensitive to clindamycin.

Hidradenitis suppurativaLevel of Evidence [C, G]

Data from a prospective, observational cohort study and a retrospective cohort study suggest that clindamycin, in combination with rifampin, may be beneficial for the treatment of hidradenitis suppurativa Ref. Based on the European S1 guideline on hidradenitis suppurativa/acne inversa, clindamycin, in combination with rifampin, is an effective and recommended agent for the treatment of hidradenitis suppurativa.

MalariaLevel of Evidence [G]

Based on the CDC guidelines for the treatment of malaria, clindamycin, in combination with quinidine or quinine, is effective and recommended for the treatment of malaria.

Neutropenic fever, empiric therapy for low-risk cancer patients (alternative agent for penicillin-allergic patients)Level of Evidence [B, G]

Data from a prospective, randomized, open-label study support the use of clindamycin (in combination with ciprofloxacin) for the outpatient management of neutropenic fever in low-risk cancer patients Ref. Based on the IDSA guidelines for the use of antimicrobial agents in neutropenic patients with cancer and the American Society of Clinical Oncology (ASCO) and IDSA guidelines for the outpatient management of fever and neutropenia in adults treated for malignancy, clindamycin (in combination with ciprofloxacin) is an effective and recommended agent for the management of neutropenic fever in low-risk cancer patients.

Odontogenic infectionLevel of Evidence [B]

Data from two randomized, prospective, blinded (one single-blind, one double-blind) studies support the use of clindamycin for the treatment of odontogenic infections Ref.

Pneumocystis jirovecii pneumonia, treatmentLevel of Evidence [G]

Based on the US Department of Health and Human Services (HHS) guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, clindamycin (with primaquine) is an effective and recommended alternative regimen for the treatment of Pneumocystis jirovecii pneumonia in HIV-infected adolescents and adults.

Pneumonia due to methicillin-resistant Staphylococcus aureusLevel of Evidence [G]

Based on the IDSA guidelines for the treatment of methicillin-resistant S. aureus infections in adults, clindamycin is effective and recommended in the treatment of community-acquired methicillin-resistant S. aureus pneumonia.

Prosthetic joint infectionLevel of Evidence [C, G]

Based on the IDSA guidelines for the management of prosthetic joint infection, clindamycin is an effective and recommended alternative agent for the treatment of prosthetic joint infection due to Cutibacterium acnes.

Clinical experience suggests the utility of clindamycin as chronic suppressive treatment of prosthetic joint infection caused by methicillin-resistant staphylococci Ref.

Rhinosinusitis, acute bacterialLevel of Evidence [C, G]

Based on the IDSA guidelines for acute bacterial rhinosinusitis (ABRS) in children and adults, clindamycin (in combination with cefixime or cefpodoxime) is an effective and recommended therapy for the treatment of ABRS.

Clinical experience suggests the utility of clindamycin (in combination with cefixime or cefpodoxime) for the treatment of ABRS Ref.

Streptococcal (group A) pharyngitis and chronic carriageLevel of Evidence [G]

Based on the IDSA guidelines for the diagnosis and management of group A streptococcal pharyngitis, clindamycin is an effective and recommended alternative agent for the treatment of streptococcal pharyngitis and an option for treatment of chronic group A streptococcal carriage.

Surgical prophylaxisLevel of Evidence [G]

Based on the American Society of Health-System Pharmacists (ASHP) clinical practice guidelines for antimicrobial prophylaxis in surgery, clindamycin, given as an alternative antibiotic in patients with beta-lactam allergy requiring surgical prophylaxis, is effective and recommended for a number of surgical procedures.

Toxoplasma gondii encephalitis and pneumonitis (treatment/long-term maintenance)Level of Evidence [G]

Based on the US Department of Health and Human Services guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents and the American Society of Transplantation Infectious Diseases Community of Practice guidelines on parasitic infections in solid organ transplantation, clindamycin (with pyrimethamine and leucovorin) is an effective and recommended alternative regimen for the treatment and long-term maintenance therapy of Toxoplasma gondii encephalitis and pneumonitis.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Lincosamides

Clinical Practice Guidelines

Anthrax:

WHO, “Anthrax in Humans and Animals,” 2008

Diabetic Foot Infection:

IDSA, “The Diagnosis and Treatment of Diabetic Foot Infections,” 2012

Infective Endocarditis:

“AHA 2007 Guidelines for the Prevention of Infective Endocarditis,” April 2007

Malaria:

CDC, “Guidelines for Treatment of Malaria in the United States,” Table - July 2013

CDC, “Treatment of Malaria (Guidelines for Clinicians),” July 2013

WHO, “Guidelines for the Treatment of Malaria,” 2010

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections:

Infectious Diseases Society of America, “Practice Guidelines for the Treatment of Methicillin-Resistant Staphylococcus aureus,” February 2011

Neutropenic Fever:

ASCO/IDSA, "Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy," February 2018.

Opportunistic Infections:

HHS, Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children, November 2013

HHS, Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, September 2017

Osteomyelitis, Native Vertebral:

IDSA, "Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults," 2015

Perinatal Group B Streptococcal Disease:

ACOG, “Prevention of Group B Streptococcal Early-Onset Disease in Newborns”, 2019

Pharyngitis, Group A Streptococci:

IDSA, “Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis,” September 2012

Pneumonia, Community-Acquired:

ATS/IDSA, "Diagnosis and Treatment of Adults With Community-Acquired Pneumonia," 2019. Note: Information contained within this monograph is pending revision based on these more recent guidelines.

IDSA/PIDS, "The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age," 2011

Prosthetic Joint Infection:

IDSA, “Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline,” January 2013

Rhinosinusitis:

IDSA, “Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” 2012

Sexually-Transmitted Disease:

CDC, “Sexually Transmitted Diseases Treatment Guidelines,” June 2015.

Skin and Soft-tissue Infection:

IDSA, “Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections,” June 2014

Surgical Prophylaxis:

ASHP, “Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,” February 2013

Administration: IM

Deep IM sites, rotate sites. Do not exceed 600 mg in a single injection.

Administration: IV

Never administer undiluted as bolus; administer by IV intermittent infusion over at least 10 to 60 minutes, at a maximum rate of 30 mg/minute (do not exceed 1,200 mg/hour). Final concentration for administration should not exceed 18 mg/mL.

Administration: Injectable Detail

pH: 6 to 6.3 (usual); 5.5 to 7 (range)

Administration: Oral

Capsule should be taken with a full glass of water to avoid esophageal irritation; shake oral solution well before use; may administer with or without meals.

Administration: Pediatric

Oral: Capsule should be taken with a full glass of water to avoid esophageal irritation; shake oral solution well before use; may administer with or without meals

Parenteral:

IM: Administer undiluted deep IM; rotate sites. Do not exceed 600 mg in a single injection.

IV: Infuse over at least 10 to 60 minutes, at a rate not to exceed 30 mg/minute; hypotension and cardiopulmonary arrest have been reported following rapid IV administration

Storage/Stability

Oral: Store at 20°C to 25°C (68°F to 77°F). Do not refrigerate the reconstituted oral solution (it will thicken); the solution is stable for 2 weeks at room temperature.

IV: Store intact vials and premixed bags at 20°C to 25°C (68°F to 77°F). Infusion solution in NS or D5W solution is stable for 16 days at room temperature, 32 days refrigerated, or 8 weeks frozen. After initial use, discard any unused portion of vial after 24 hours.

Preparation for Administration: Adult

Injection: Never administer undiluted as bolus. For IV infusion, dilute vials with 50 to 100 mL of compatible diluent (eg, D5W, NS); concentration of clindamycin for IV infusion should not exceed 18 mg/mL.

Oral solution: Reconstitute bottles of 100 mL with 75 mL of water. Add a large portion of the water and shake vigorously; add the remainder of the water and shake until the solution is uniform. When reconstituted with water, each 5 mL of solution contains clindamycin palmitate hydrochloride equivalent to clindamycin 75 mg.

Preparation for Administration: Pediatric

Oral: Reconstitute powder for oral solution with appropriate amount of water as specified on the bottle. Shake vigorously until suspended.

Parenteral: IV: Dilute with a compatible diluent (eg, D5W, NS) to a final concentration not to exceed 18 mg/mL

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat or prevent bacterial infections.

Frequently reported side effects of this drug

• Abdominal pain

• Nausea

• Vomiting

• Bad taste

• Diarrhea

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Clostridioides (formerly Clostridium) difficile-associated diarrhea like abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools

• Injection site pain, edema, or redness

• Joint pain

• Joint swelling

• Unable to pass urine

• Change in amount of urine passed

• Yellow skin

• Swollen glands

• Vaginal pain, itching, and discharge

• Stevens-Johnson syndrome/toxic epidermal necrolysis like red, swollen, blistered, or peeling skin (with or without fever); red or irritated eyes; or sores in mouth, throat, nose, or eyes

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Contraindications

Hypersensitivity to clindamycin, lincomycin, or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Oral clindamycin: Infants <30 days of age.

Warnings/Precautions

Concerns related to adverse effects:

• Colitis: [US Boxed Warning]: Can cause severe and possibly fatal colitis. Should be reserved for serious infections where less toxic antimicrobial agents are inappropriate. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. C. difficile-associated diarrhea (CDAD) must be considered in all patients who present with diarrhea following antibiotic use. CDAD has been observed >2 months postantibiotic treatment. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Institute appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation as clinically indicated.

• Hypersensitivity: Severe hypersensitivity reactions, including severe skin reactions (eg, drug reaction with eosinophilia and systemic symptoms [DRESS], Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN]), some fatal, and anaphylactic reactions, including anaphylactic shock, have been reported. Permanently discontinue treatment and institute appropriate therapy if these reactions occur.

• Superinfection: Use may result in overgrowth of nonsusceptible organisms, particularly yeast. Should superinfection occur, appropriate measures should be taken as indicated by the clinical situation.

Disease-related concerns:

• GI disease: Use with caution in patients with a history of GI disease, particularly colitis.

• Hepatic impairment: Use with caution in patients with moderate to severe liver disease, however, when administered at every-8-hour intervals, drug accumulation is rare. Monitor hepatic enzymes periodically as dosage adjustments may be necessary in patients with severe liver disease.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Atopic patients: Use with caution in atopic patients.

• Elderly: A subgroup of older patients with associated severe illness may tolerate diarrhea less well. Monitor carefully for changes in bowel frequency.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer’s labeling.

• Tartrazine: Some products may contain tartrazine (FD&C yellow no. 5), which may cause allergic reactions in certain individuals. Allergy is frequently seen in patients who also have an aspirin hypersensitivity.

Other warnings/precautions:

• Administration (IV): Do not inject IV undiluted as a bolus. Product should be diluted in compatible fluid and infused over 10 to 60 minutes.

• Appropriate use: Not appropriate for use in the treatment of meningitis due to inadequate penetration into the CSF.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Clindamycin has not been studied in the elderly; however, since it is eliminated principally by nonrenal mechanisms, major alteration in its pharmacokinetics are not expected. Elderly patients are often at a higher risk for developing serious colitis and require close monitoring.

Pregnancy Considerations

Clindamycin crosses the placenta and can be detected in the cord blood and fetal tissue (Philipson 1973; Weinstein 1976). Clindamycin injection contains benzyl alcohol which may also cross the placenta.

Clindamycin pharmacokinetics are not affected by pregnancy (Philipson 1976; Weinstein 1976).

Clindamycin is recommended for use in pregnant women for the prophylaxis of group B streptococcal disease in newborns (alternative therapy) (ACOG 782 2019); prophylaxis and treatment of Toxoplasma gondii encephalitis (alternative therapy), or Pneumocystis pneumonia (PCP) (alternative therapy) (HHS [OI adult ] 2019); bacterial vaginosis (CDC [Workowski 2015]); anthrax (Meaney-Delman 2014); or malaria (CDC 2019). Clindamycin is also one of the antibiotics recommended for prophylactic use prior to cesarean delivery and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (ACOG 199 2018).

Breast-Feeding Considerations

Clindamycin is present in breast milk.

The relative infant dose (RID) of clindamycin is 1.2% to 4.7% when calculated using the highest verifiable breast milk concentration located and compared to an infant therapeutic dose of 10 to 40 mg/kg/day.

In general, breastfeeding is considered acceptable when the RID is <10% (Anderson 2016; Ito 2000).

Using the highest verifiable milk concentration (3.1 mcg/mL), the estimated daily infant dose via breast milk is 0.465 mg/kg/day. This milk concentration was obtained following maternal administration of oral clindamycin 150 mg three times daily for at least 1 week (Stéen 1982). The manufacturer reports that clindamycin breast milk concentrations range from <0.5 to 3.8 mcg/mL following doses of 150 mg orally to 600 mg IV.

One case of bloody stools in an infant occurred after a mother received clindamycin while breastfeeding; however, a causal relationship was not confirmed (Mann 1980). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora.

According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother; alternate therapies may be preferred. Additional guidelines recommend to avoid clindamycin in breastfeeding women if possible; monitor breastfeeding infants for GI disturbances, diarrhea, and bloody stools if maternal treatment is required (WHO 2002).

Lexicomp Pregnancy & Lactation, In-Depth

• Clindamycin (Systemic)

Briggs' Drugs in Pregnancy & Lactation

• Clindamycin

Adverse Reactions

Frequency not defined.

Cardiovascular: Hypotension (rare; IV administration), thrombophlebitis (IV)

Central nervous system: Metallic taste (IV)

Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme (rare), exfoliative dermatitis (rare), maculopapular rash, pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis, urticaria, vesiculobullous dermatitis

Gastrointestinal: Abdominal pain, antibiotic-associated colitis, Clostridioides (formerly Clostridium) difficile-associated diarrhea, diarrhea, esophageal ulcer, esophagitis, nausea, pseudomembranous colitis, unpleasant taste (IV), vomiting

Genitourinary: Azotemia, oliguria, proteinuria, vaginitis

Hematologic & oncologic: Agranulocytosis, eosinophilia (transient), neutropenia (transient), thrombocytopenia

Hepatic: Abnormal hepatic function tests, jaundice

Hypersensitivity: Anaphylactic shock, anaphylactoid reaction (rare), anaphylaxis, angioedema, hypersensitivity reaction

Immunologic: DRESS syndrome

Local: Abscess at injection site (IM), induration at injection site (IM), irritation at injection site (IM), pain at injection site (IM)

Neuromuscular & skeletal: Polyarthritis (rare)

Renal: Renal insufficiency (rare)

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Aniline Dye Allergy
• Lincosamide Allergy

Metabolism/Transport Effects

Substrate of CYP3A4 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions Open Interactions

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

CYP3A4 Inducers (Strong): May decrease the serum concentration of Clindamycin (Systemic). Refer to the specific clindamycin (systemic) - rifampin drug interaction monograph for information concerning that combination. Exceptions: RifAMPin. Risk C: Monitor therapy

Kaolin: May decrease the absorption of Lincosamide Antibiotics. Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Mecamylamine: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Mecamylamine. Risk X: Avoid combination

Neuromuscular-Blocking Agents: Lincosamide Antibiotics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Risk D: Consider therapy modification

Monitoring Parameters

Observe for changes in bowel frequency. Monitor for colitis and resolution of symptoms. In severe liver disease monitor liver function tests periodically; during prolonged therapy monitor CBC, liver and renal function tests periodically.

Advanced Practitioners Physical Assessment/Monitoring

Assess culture/sensitivity tests and patient's allergy history prior to beginning therapy. Obtain CBC, renal function tests, liver function tests periodically with prolonged therapy. Obtain liver function tests in patients with severe hepatic impairment. Assess for effectiveness of treatment. Test for C. difficile if patient develops diarrhea.

Nursing Physical Assessment/Monitoring

Check lab results and report abnormalities. Monitor for severe or bloody diarrhea and send a specimen to the lab for C.difficile. Monitor for improvement with infection.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as hydrochloride [strength expressed as base]:

Cleocin: 75 mg, 150 mg [contains brilliant blue fcf (fd&c blue #1), tartrazine (fd&c yellow #5)]

Cleocin: 300 mg [contains brilliant blue fcf (fd&c blue #1)]

Generic: 75 mg, 150 mg, 300 mg

Kit, Injection, as phosphate [strength expressed as base]:

CLIN Single Use: 300 mg/2 mL [DSC] [contains benzyl alcohol, edetate disodium]

Solution, Injection, as phosphate [strength expressed as base]:

Cleocin Phosphate: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL); 9 g/60 mL (60 mL) [contains benzyl alcohol, edetate disodium]

Generic: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL); 9000 mg/60 mL (60 mL); 9 g/60 mL (60 mL)

Solution, Intravenous, as phosphate [strength expressed as base]:

Cleocin in D5W: 600 mg/50 mL (50 mL [DSC]) [contains benzyl alcohol, edetate disodium]

Cleocin Phosphate: 300 mg/2 mL (2 mL); 600 mg/4 mL (4 mL); 900 mg/6 mL (6 mL) [contains benzyl alcohol, edetate disodium]

Generic: 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL); 300 mg/2 mL (2 mL [DSC]); 600 mg/4 mL (4 mL [DSC]); 900 mg/6 mL (6 mL)

Solution, Intravenous, as phosphate [strength expressed as base, preservative free]:

Cleocin in D5W: 300 mg/50 mL (50 mL [DSC]) [contains benzyl alcohol, edetate disodium]

Cleocin in D5W: 300 mg/50 mL (50 mL [DSC]); 600 mg/50 mL (50 mL [DSC]) [contains edetate disodium]

Cleocin in D5W: 900 mg/50 mL (50 mL [DSC]) [contains benzyl alcohol, edetate disodium]

Cleocin in D5W: 900 mg/50 mL (50 mL [DSC]) [contains edetate disodium]

Generic: 300 mg/50 mL (50 mL); 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL); 300 mg/50 mL in NaCl 0.9% (50 mL); 600 mg/50 mL in NaCl 0.9% (50 mL); 900 mg/50 mL in NaCl 0.9% (50 mL)

Solution Reconstituted, Oral, as palmitate hydrochloride [strength expressed as base]:

Cleocin: 75 mg/5 mL (100 mL) [contains ethylparaben]

Generic: 75 mg/5 mL (100 mL)

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral, as hydrochloride [strength expressed as base]:

Dalacin C: 150 mg, 300 mg

Generic: 150 mg, 300 mg

Solution, Injection:

Dalacin C Phosphate: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL) [contains benzyl alcohol, edetate disodium]

Generic: 150 mg/mL (2 mL, 4 mL, 6 mL, 60 mL, 120 mL)

Solution, Intravenous, as phosphate [strength expressed as base]:

Generic: 300 mg/50 mL (50 mL); 600 mg/50 mL (50 mL); 900 mg/50 mL (50 mL)

Solution Reconstituted, Oral, as palmitate hydrochloride [strength expressed as base]:

Dalacin C Palmitate: 75 mg/5 mL (100 mL) [contains ethylparaben]

Anatomic Therapeutic Chemical (ATC) Classification

• G01AA10
• J01FF01

Generic Available (US)

May be product dependent

Pricing: US

Capsules (Cleocin Oral)

75 mg (per each): $0.26

150 mg (per each): $0.17

300 mg (per each): $0.34

Capsules (Clindamycin HCl Oral)

75 mg (per each): $0.72

150 mg (per each): $0.68 - $1.19

300 mg (per each): $3.72 - $3.76

Solution (Cleocin Phosphate Injection)

9 g/60 mL (per mL): $0.46

300 mg/2 mL (per mL): $1.47

600 mg/4 mL (per mL): $0.87

900 mg/6 mL (per mL): $0.84

Solution (Cleocin Phosphate Intravenous)

300 mg/2 mL (per mL): $2.37

600 mg/4 mL (per mL): $1.32

900 mg/6 mL (per mL): $1.14

Solution (Clindamycin Phosphate in D5W Intravenous)

300 mg/50 mL (per mL): $0.17 - $0.20

600 mg/50 mL (per mL): $0.26 - $0.30

900 mg/50 mL (per mL): $0.31 - $0.36

Solution (Clindamycin Phosphate in NaCl Intravenous)

300 mg/50 mL 0.9% (per mL): $0.17

600 mg/50 mL 0.9% (per mL): $0.26

900 mg/50 mL 0.9% (per mL): $0.31

Solution (Clindamycin Phosphate Injection)

9 g/60 mL (per mL): $0.47 - $0.59

300 mg/2 mL (per mL): $1.32 - $1.78

600 mg/4 mL (per mL): $0.78 - $1.11

900 mg/6 mL (per mL): $0.76 - $0.95

Solution (reconstituted) (Cleocin Oral)

75 mg/5 mL (per mL): $0.37

Solution (reconstituted) (Clindamycin Palmitate HCl Oral)

75 mg/5 mL (per mL): $0.50 - $1.08

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Reversibly binds to 50S ribosomal subunits preventing peptide bond formation thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism

Pharmacodynamics/Kinetics

Absorption: Oral, hydrochloride: Rapid (90%); clindamycin palmitate must be hydrolyzed in the GI tract before it is active

Distribution: Distributed in body fluids and tissues; no significant levels in CSF, even with inflamed meninges

Protein binding: 94%

Metabolism: Biologically inactive clindamycin phosphate (intravenous formulation) is rapidly converted to active clindamycin. Clindamycin is metabolized predominantly by CYP3A4, with minor contribution by CYP3A5, to form clindamycin sulfoxide (major metabolite) and N-desmethylclindamycin (minor metabolite)

Bioavailability: Oral: ~90%

Half-life elimination:

Neonates: Premature: 8.7 hours; Full-term: 3.6 hours

Infants 1 month to 1 year: 3 hours

Children: ~2.5 hours

Adults: 3 hours

Elderly (oral) ~4 hours (range: 3.4 to 5.1 hours)

Time to peak, serum: Oral: Within 60 minutes; IM: 1 to 3 hours

Excretion: Urine (~10%) and feces (3.6%) as active drug and metabolites

Dental Use

Alternate oral antibiotic for prevention of infective endocarditis in individuals allergic to penicillins or ampicillin, when amoxicillin cannot be used; alternate IM or IV antibiotic for prevention of infective endocarditis in patients allergic to penicillins or ampicillin and unable to take oral medication; alternate oral antibiotic for prophylaxis for dental patients with total joint replacement who are allergic to penicillin; alternate IV antibiotic for prophylaxis for dental patients with total joint replacement who are allergic to penicillin and unable to take oral medications; alternate antibiotic in the treatment of common orofacial infections caused by aerobic gram-positive cocci and susceptible anaerobes; treatment of periodontal disease

* See Uses in AHFS Essentials for additional information.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Dental Health Professional Considerations

About 1% of clindamycin users develop pseudomembranous colitis. Symptoms may occur 2 to 9 days after initiation of therapy; however, it has never occurred with the 1-dose regimen of clindamycin used to prevent bacterial endocarditis.

Effects on Dental Treatment

No significant effects or complications reported (See Dental Health Professional Considerations)

Effects on Bleeding

No information available to require special precautions

Dental Usual Dosing

Orofacial infection:

Children:

Oral: 10-20 mg/kg/day in 3-4 equally divided doses

IV: 15-25 mg/kg/day in 3-4 equally divided doses

Adults:

Oral: 150-450 mg/dose for 7 days; maximum dose: 1.8 g/day

IV: 600-900 mg every 8 hours

Treatment of periodontal disease: Oral: 300 mg every 8 hours for 8 days

Infective endocarditis prophylaxis:

Children:

Oral: 20 mg/kg 30-60 minutes before procedure

IM, IV: 20 mg/kg 30-60 minutes before procedure. Note: Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.

Adults:

Oral: 600 mg 30-60 minutes before procedure

IM, IV: 600 mg 30-60 minutes before procedure. Note: Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.

Prophylaxis in total joint replacement patients undergoing dental procedures which produce bacteremia:

Adults:

Oral: 600 mg 1 hour prior to procedure

IV: 600 mg 1 hour prior to procedure (for patients unable to take oral medication)

Note: In general, patients with prosthetic joint implants do not require prophylactic antibiotics prior to dental procedures. In planning an invasive oral procedure, dental consultation with the patient's orthopedic surgeon may be advised to review the risks of infection.

Related Information

• Narrow Therapeutic Index Drugs
• Prevention of Infective Endocarditis

Pharmacotherapy Pearls

In vitro susceptibility rates to clindamycin are higher in community acquired versus hospital acquired MRSA, although this may vary by geographic region. The D-zone test is recommended for detection of inducible resistance to clindamycin in erythromycin-resistant but clindamycin-susceptible isolates (Liu, 2011).

Index Terms

Clindamycin HCl; Clindamycin Hydrochloride; Clindamycin Palmitate; Clindamycin Palmitate HCl

FDA Approval Date

February 22, 1970

References

ADA Division of Legal Affairs. A legal perspective on antibiotic prophylaxis. J Am Dent Assoc. 2003;134(9):1260.[PubMed 14529001]

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.

American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.

American College of Obstetricians and Gynecologists (ACOG). Prevention of group B streptococcal early-onset disease in newborns: ACOG Committee Opinion, Number 782. Obstet Gynecol. 2019;134(1):e19-e40. doi: 10.1097/AOG.0000000000003334.[PubMed 31241599]

American Dental Association, American Academy of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc. 2003;134(7):895-899.[PubMed 12892448]

American Dental Association Council on Scientific Affairs. Combating antibiotic resistance. J Am Dent Assoc. 2004;135(4):484-487.[PubMed 15127872]

Anderson DJ, Podgorny K, Berríos-Torres SI, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(6):605-627. doi: 10.1086/676022.[PubMed 24799638]

Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52.[PubMed 27060684]

Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.

Baddour LM, Harper M. Animal bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 22, 2019b.

Baddour LM, Harper M. Human bites: evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 22, 2019a.

Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 2, 2020.

Bader MS. Diabetic foot infection. Am Fam Physician. 2008;78(1):71-79.[PubMed 18649613]

Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61(6):e26-e46. doi: 10.1093/cid/civ482.[PubMed 26229122]

Berbari E, Baddour LM. Prosthetic joint infection: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 1, 2019.

Berríos-Torres SI, Umscheid CA, Bratzler DW, et al; Healthcare Infection Control Practices Advisory Committee. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152(8):784-791. doi: 10.1001/jamasurg.2017.0904.[PubMed 28467526]

Bhagania M, Youseff W, Mehra P, Figueroa R. Treatment of odontogenic infections: an analysis of two antibiotic regimens. J Oral Biol Craniofac Res. 2018;8(2):78-81. doi: 10.1016/j.jobcr.2018.04.006.[PubMed 29892525]

Bow E. Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 6, 2018.

Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-e76.[PubMed 21880587]

Bradley JS, Peacock G, Krug SE, et al; AAP Committee on Infectious Diseases and Disaster Preparedness Advisory Council. Pediatric anthrax clinical management. Pediatrics. 2014;133(5):e1411-e1436. doi: 10.1542/peds.2014-0563.[PubMed 24777226]

Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283.[PubMed 23327981]

Cachovan G, Böger RH, Giersdorf I, et al. Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial. Antimicrob Agents Chemother. 2011;55(3):1142-1147. doi: 10.1128/AAC.01267-10.[PubMed 21173173]

Centers for Disease Control and Prevention (CDC), "Diagnosis and Treatment of Malaria." Available at http://www.cdc.gov/malaria/diagnosis_treatment/index.html. Date accessed: October 21, 2011.

Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm[PubMed 6810084]

Centers for Disease Control and Prevention (CDC). Treatment of malaria (guidelines for clinicians 2019). http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf. Published July 2013. Accessed September 28, 2015.

Cimino JE, Tierno PM Jr. Hemodialysis properties of clindamycin (7-chloro-7-deoxylincomycin). Appl Microbiol. 1969;17(3):446-448.[PubMed 5780400]

Chen KT. Postpartum endometritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 25, 2018.

Chow AW, Benninger MS, Brook I, et al; Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112.[PubMed 22438350]

Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 18, 2018.

Chu VH. Staphylococcal toxic shock syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Cleocin hydrochloride capsules (clindamycin) [prescribing information]. New York, NY: Pfizer; June 2019.

Cleocin Pediatric oral solution (clindamycin) [prescribing information]. New York, NY: Pharmacia & Upjohn Co; February 2020.

Cleocin phosphate injection [prescribing information]. New York, NY: Pharmacia & Upjohn Co; March 2020.

Dalacin C (clindamycin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; August 2019.

Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C. Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a prospective study and 1-year follow-up. Clin Exp Dermatol. 2016;41(8):852-857. doi: 10.1111/ced.12933.[PubMed 27753139]

Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93. doi: 10.1093/cid/cir073.[PubMed 21258094]

Gall S, Koukol DH. Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. J Reprod Med. 1996;41(8):575-580.[PubMed 8866384]

Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148-154. doi: 10.1159/000228334.[PubMed 19590173]

Gerber MA, Baltimore RS, Eaton CB, et al, "Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics," Circulation, 2009, 119(11):1541-51.[PubMed 19246689]

Goldenberg DL, Sexton DJ. Septic arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 3, 2019.

Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343-351. doi: 10.1007/s11154-016-9328-5.[PubMed 26831295]

Hall G, Nord CE, Heimdahl A. Elimination of bacteraemia after dental extraction: comparison of erythromycin and clindamycin for prophylaxis of infective endocarditis. J Antimicrob Chemother. 1996;37(4):783-795.[PubMed 8722544]

Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016;164(6):425-434. doi: 10.7326/M15-1840.[PubMed 26785402]

Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy. 2009;29(5):562-577. doi: 10.1592/phco.29.5.562.[PubMed 19397464]

Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax clinical guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2):e130687. doi: 10.3201/eid2002.130687.[PubMed 24447897]

HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. March 1, 2016. Available at http://aidsinfo.nih.gov

HHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA)," July 2019. Available at https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0

HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at http://aidsinfo.nih.gov

Hicks CW, Sweeney DA, Cui X, Li Y, Eichacker PQ. An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med. 2012;38(7):1092-1104.[PubMed 22527064]

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126.[PubMed 10891521]

Jevsevar DS, Abt E. The New AAOS-ADA clinical practice guideline on prevention of orthopaedic implant infection in patients undergoing dental procedures. J Am Acad Orthop Surg. 2013;21(3):195-197.[PubMed 23457071]

Kanafani ZA. Invasive Cutibacterium (formerly Propionibacterium) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 18, 2018.

Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis. 2008;46(3):370-376. doi: 10.1086/525852.[PubMed 18181735]

Krause PJ, Vannier EG. Babesiosis: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 20, 2019.

Lalani T. Overview of osteomyelitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 30, 2018.

Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009;9(5):281-290.[PubMed 19393958]

Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics. 2013;131(3):e964-e999.[PubMed 23439909]

Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012;54(12):e132-e173.[PubMed 22619242]

Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med. 1990;150(4):790-797.[PubMed 2183732]

Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285-292.[PubMed 21217178]

Mackeen AD, Packard RE, Ota E, Speer L. Antibiotic regimens for postpartum endometritis. Cochrane Database Syst Rev. 2015;(2):CD001067. doi: 10.1002/14651858.CD001067.pub3.[PubMed 25922861]

Malacoff RF, Finkelstein FO, Andriole VT. Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin. Antimicrob Agents Chemother. 1975;8(5):574-580.[PubMed 1211913]

Mann CF. Clindamycin and breast-feeding. Pediatrics. 1980;66(6):1030-1031.[PubMed 7454470]

Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014;20(2). doi: 10.3201/eid2002.130611.[PubMed 24457117]

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Resp Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST.[PubMed 31573350]

Osmon DR, Berbari EF, Berendt AR, et al; Infectious Diseases Society of America. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(1):e1-e25.[PubMed 23223583]

Osmon DR, Tande AJ. Osteomyelitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 20, 2019.[PubMed 23223583]

Patel ZM, Hwang PH. Uncomplicated acute sinusitis and rhinosinusitis in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 24, 2018.[PubMed Patel.2018]

Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin Pharmacol Ther. 1976;19(1):68-77.[PubMed 1245094]

Philipson A, Sabath LD, Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med, 1973;288(23):1219-1221. doi: 10.1056/NEJM197306072882307.[PubMed 4700555]

Rosenfeld RM. Clinical Practice. Acute sinusitis in adults. N Engl J Med. 2016;375(10):962-970. doi: 10.1056/NEJMcp1601749.[PubMed 27602668]

Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2)(suppl):S1-S39. doi: 10.1177/0194599815572097.[PubMed 25832968]

Rubenstein EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993;71(11):3640-3646.[PubMed 8490912]

Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild-to-moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med. 1996;124(9):792-802.[PubMed 8610948]

Sanchez E, Vannier E, Wormser GP, Hu LT. Diagnosis, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: a review. JAMA. 2016;315(16):1767-1777. doi: 10.1001/jama.2016.2884.[PubMed 27115378]

Schwartz BS, Mawhorter SD; AST Infectious Diseases Community of Practice. Parasitic infections in solid organ transplantation. Am J Transplant. 2013;13(suppl 4):280-303. doi: 10.1111/ajt.12120.[PubMed 23465021]

Sendi P, Christensson B, Uçkay I, et al; GBS PJI study group. Group B streptococcus in prosthetic hip and knee joint-associated infections. J Hosp Infect. 2011;79(1):64-69. doi: 10.1016/j.jhin.2011.04.022.[PubMed 21764170]

Shulman ST, Bisno AL, Clegg HW, et al; Infectious Diseases Society of America. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-e102.[PubMed 22965026]

Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015;146(1):11-16. doi: 10.1016/j.adaj.2014.11.012.[PubMed 25569493]

Solomkin JS, Mazuski JE, Bradley JS, et al, "Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America," Clin Infect Dis, 2010, 50(2):133-64.[PubMed PMID:20034345[PubMed - indexed for MEDLINE] Free full text ]

Spelman D, Baddour LM. Cellulitis and skin abscess in adults: treatment. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 2, 2020.

Stéen B, Rane A. Clindamycin passage into human milk. Br J Clin Pharmacol. 1982;13(5):661-664.[PubMed 7082533 ]

Stevens DL, Baddour LM. Necrotizing soft tissue infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed July 20, 2018.

Stevens DL. Invasive group A streptococcal infection and toxic shock syndrome: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 18, 2019.

Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published online ahead of print June 18, 2014]. Clin Infect Dis. 2014;59(2):147-159. doi: 10.1093/cid/ciu296.[PubMed 24947530]

Tancawan AL, Pato MN, Abidin KZ, et al. Amoxicillin/Clavulanic acid for the treatment of odontogenic infections: a randomised study comparing efficacy and tolerability versus clindamycin. Int J Dent. 2015;2015:472470. doi: 10.1155/2015/472470.[PubMed 26300919]

Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211.[PubMed 29461916]

Thomas CF, Limper AH. Treatment and prevention of pneumocystis pneumonia in HIV-uninfected patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 6, 2018.

Tomblyn M, Chiller T, Einsele H, et al, "Guidelines for Preventing Infectious Complications Among Hematopoietic Cell Transplantation Recipients: A Global Perspective," Biol Blood Marrow Transplant, 2009, 15(10):1143-238.[PubMed 19747629]

Trotman RL, Williamson JC, Shoemaker DM, et al, “Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,” Clin Infect Dis, 2005, 41(8):1159-66.[PubMed 16163635]

US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. March 1, 2016. http://aidsinfo.nih.gov

US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/0. Accessed October 20, 2017.

Vannier E, Krause PJ. Human babesiosis. N Engl J Med. 2012;366(25):2397-2407. doi: 10.1056/NEJMra1202018.[PubMed 22716978]

Warady BA, Bakkaloglu S, Newland J, et al "Consensus Guidelines for the Prevention and Treatment of Catheter-Related Infections and Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis: 2012 Update," Perit Dial Int, 2012, 32(Suppl 2):S32-86.[PubMed 22851742]

Weinstein AJ, Gibbs RS, Gallagher M. Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol. 1976;124(7):688-691.[PubMed 943947]

Weintrob AC, Sexton DJ. Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 11, 2018.

Wilson W, Taubert KA, Gewitz M, et al, "Prevention of Infective Endocarditis. Guidelines From the American Heart Association," Circulation, 2007, 115:1-20.

Wilson W, Taubert KA, Gewitz M, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis. Guidelines from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group [published correction appears in Circulation. 2007;116(15):e376-e377]. Circulation. 2007;116(15):1736-1754.[PubMed 17446442]

Wong CJ, Stevens DL. Serious group A streptococcal infections. Med Clin North Am. 2013;97(4):721-736.[PubMed 23809722]

Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep. 2015;64(33):924]. MMWR Recomm Rep. 2015;64(RR-03):1-137.[PubMed 26042815]

World Health Organization (WHO), Anthrax in Humans and Animals, 4th ed, 2008. http://whqlibdoc.who.int/publications/2008/9789241547536_eng.pdf

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. http://www.who.int/maternal_child_adolescent/documents/55732/en/

Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America [published correction appears in Clin Infect Dis. 2007;45(7):941]. Clin Infect Dis. 2006;43(9):1089-1134. doi: 10.1086/508667.[PubMed 17029130]

Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644. doi: 10.1111/jdv.12966.[PubMed 25640693]

Brand Names: International

Acnocin (TH); Albiotin (ID); Aledo Gel (TW); BB (TW); Chinacin-T (TH); Cleocin (BB); Cleocin HCl (AU, PK, TW); Cleocin T (TR, TW); Clicin (VN); Clidacor (ID); Clidets (VE); Climadan (ID, SG); Climax (BD); Clinacin (AE, CY, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Clinbac (PH); Clinbercin (ID); Clincin (TW); Clinda (DE); Clinda-P (TH); Clindabact (LK); Clindac-A (IN); Clindacid (PY); Clindacin (AE, BH, CY, IQ, IR, JO, KW, LB, LY, OM, PE, SA, SY, YE); Clindagen (PH); Clindal (PH); Clindala (ID); Clindalin (TH); Clindam (EG); Clindatec (PH); Clindavid (TH); Clindox (JO); Clinott (TH); Cliz (PH); Dacin (SG); Daclin (BD); Daklin (PH); Dalace (PH); Dalacin (AE, BD, ES, HU, IE, IS, JO, QA, TH, UA); Dalacin C (AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DK, DO, EC, EE, EG, ET, GB, GH, GM, GN, GR, GT, HK, HN, HR, ID, IE, IL, IN, IQ, IR, IT, KE, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PL, PT, QA, RO, SA, SC, SD, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TZ, UA, UG, UY, VN, YE, ZA, ZM, ZW); Dalacine (FR); Dalaclin (PH); Dalamed (PH); Dalcap (IN); Damicine (CO); Damiclin V (CO); Euroclin (EC); Fullgram (KR); Jutaclin (DE); Klimicin (CZ); Klincyn (PH); Klinda RX (TH); Klindamycin (TH); Lacin (TH); Lanacin (AE, CY, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Lando (ID); Librodan (ID); Lindacin (MY, TW); Luoqing (CN); Magicmycin (EG); Neotasin (KR); Nildacin (ID); Peldacyn (PH); Potecin (PH); Qualiclinda (HK); Queritan (PY); Tidact (LK, PH, TW); Todacin (TH)

Last Updated 3/21/20